Exploring the Pipeline of Novel Therapies for Inflammatory Bowel Disease; State of the Art Review.

ABSTRACT: Crohn's disease (CD) and ulcerative colitis (UC), known as inflammatory bowel diseases (IBD), are characterized by chronic inflammation of the gastrointestinal tract. Over the last two decades, numerous medications have been developed and repurposed to induce and maintain remission in IBD patients. Despite the approval of multiple drugs, the major recurring issues continue to be primary non-response and secondary loss of response, as well as short- and long-term adverse events. Most clinical trials show percentages of response under 60%, possibly as a consequence of strict inclusion criteria and definitions of response. That is why these percentages appear to be more optimistic in real-life studies. A therapeutic ceiling has been used as a term to define this invisible bar that has not bee

SUBMITTER: Zurba Y 

PROVIDER: S-EPMC10045261 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature